Arachidonic acid-derived signaling lipids and functions in impaired healing

Wound Repair and Regeneration

Volumn 23, Issue 5, 2015, Pages 644-656

  Dhall, Sandeep ^a,b   Wijesinghe, Dayanjan Shanaka ^c,d,e,f   Karim, Zubair A ^f   Castro, Anthony ^a   Vemana, Hari Priya ^g   Khasawneh, Fadi T ^f   Chalfant, Charles E ^d,e,f   Martins Green, Manuela ^a,b  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b University of California ^*  (United States)

^c VIRGINIA COMMONWEALTH UNIVERSITY SCHOOL OF MEDICINE   (United States)

^d VETERANS AFFAIRS MEDICAL CENTER   (United States)

^e VIRGINIA COMMONWEALTH UNIVERSITY   (United States)

^f VIRGINIA COMMONWEALTH UNIVERSITY   (United States)

^g WESTERN UNIVERSITY OF HEALTH SCIENCES   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

11 HYDROXYEICOSATETRANOIC ACID; 12 HYDROXYEICOSATETRANOIC ACID; 15 HYDROXYEICOSATETRANOIC ACID; 6 OXOPROSTAGLANDIN F1 ALPHA; ARACHIDONIC ACID; ICOSANOID; LIPID; THROMBOXANE A2; THROMBOXANE B2; UNCLASSIFIED DRUG; PANCREATIC ELASTASE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; BLOOD VESSEL; CHRONIC WOUND; CONTROLLED STUDY; EXTRACELLULAR MATRIX; HEMOSTASIS; HUMAN; INFLAMMATION; LIPIDOMICS; MOUSE; NONHUMAN; OXIDATIVE STRESS; PRIORITY JOURNAL; THROMBOCYTE AGGREGATION; WOUND HEALING IMPAIRMENT; ANIMAL; C57BL MOUSE; DISEASE MODEL; DRUG EFFECTS; INJURIES; LIPID METABOLISM; MASS SPECTROMETRY; METABOLISM; PATHOLOGY; PIG; SIGNAL TRANSDUCTION; SKIN; WOUND HEALING; WOUNDS AND INJURIES;

ANIMALS; ARACHIDONIC ACID; DISEASE MODELS, ANIMAL; LIPID METABOLISM; MASS SPECTROMETRY; MICE; MICE, INBRED C57BL; OXIDATIVE STRESS; PANCREATIC ELASTASE; SIGNAL TRANSDUCTION; SKIN; SWINE; WOUND HEALING; WOUNDS AND INJURIES;

EID: 84945458515     PISSN: 10671927     EISSN: 1524475X     Source Type: Journal    
DOI: 10.1111/wrr.12337     Document Type: Article

References (69)

1. Lazarus GS, Cooper DM, Knighton DR, Margolis DJ, Pecoraro RE, Rodeheaver G, Robson MC,. Definitions and guidelines for assessment of wounds and evaluation of healing. Wound Repair Regen 1994; 2: 165-70.
2. Mustoe TA, O'Shaughnessy, K, Kloeters, O., Chronic wound pathogenesis and current treatment strategies: a unifying hypothesis. Plast Reconstr Surg 2006; 117: 35S-41S.
3. Demidova-Rice T, Hamblin MR, Herman IM., Acute and impaired wound healing: pathophysiology and current methods for drug delivery, part 2: role of growth factors in normal and pathological wound. Adv Skin Wound Care 2012; 25: 349-70.
4. Nicolaou A., Eicosanoids in skin inflammation. Prostaglandins Leukot Essent Fatty Acids 2013; 88: 131-8.
5. Arturson G., Prostaglandins in human burn-wound secretion. Burns 1977; 3: 112-8.
6. Turner SR., Polymorphonulcear leukocyte chemotaxis toward oxidized lipid components of cell membranes. J Exp Med 1975; 141: 1437-41.
7. Goetzl EJ, Woods JM, Gorman RR., Stimulation of human eosinophil and neutrophil polymorphonuclear leukocyte chemotaxis and random migration by 12-L-hydroxy-5,8,10,14-eicosatetraenoic acid. J Clin Invest 1977; 59: 179-83.
8. Moncada S, Gryglewski RJ, Bunting S, Vane JR., A lipid peroxide inhibits the enzyme in blood vessel microsomes that generates from prostaglandin endoperoxides the substance (prostaglandin X) which prevents platelet aggregation. Prostaglandins 1976; 12: 715-37.
9. Moncada S., Human arterial and venous tissues generate prostacyclin (prostaglandin X), a potent inhibitor of platelet aggregation. Lancet 1977; 309: 18-21.
10. Saynor R, Verel D, Gillott T., The long-term effect of dietary supplementation with fish lipid concentrate on serum lipids, bleeding time, platelets and angina. Atherosclerosis 1984; 50: 3-10.
11. Wenk MR., The emerging field of lipidomics. Nat Rev Drug Discov 2005; 4: 594-610.
12. Wijesinghe DS, Chalfant CE., Systems-level lipid analysis methodologies for qualitative and quantitative investigation of lipid signaling events during wound healing. Adv Wound Care 2013; 2: 538-48.
13. Meikle PJ, Wong G, Barlow CK, Kingwell BA., Lipidomics: potential role in risk prediction and therapeutic monitoring for diabetes and cardiovascular disease. Pharmacol Ther 2014; 143: 12-23.
14. Balsinde J, Winstead MV, Dennis EA., Phospholipase A2 regulation of arachidonic acid mobilization. FEBS Lett 2002; 531: 2-6.
15. Kuehl F, Egan R., Prostaglandins, arachidonic acid, and inflammation. Science 1980; 210: 978-84.
16. Mruwat R, Cohen Y, Yedgar S., Phospholipase A 2 inhibition as potential therapy for inflammatory skin diseases. Immunotherapy 2013; 5: 315-7.
17. Montuschi P, Barnes PJ, Roberts LJ., Isoprostanes: markers and mediators of oxidative stress. FASEB J 2004; 18: 1791-800.
18. Ting HJ, Khasawneh FT., Platelet function and isoprostane biology. Should isoprostanes be the newest member of the orphan-ligand family? J Biomed Sci 2010; 17: 24.
19. Spite M, Clària J, Serhan CN., Resolvins, specialized proresolving lipid mediators, and their potential roles in metabolic diseases. Cell Metab 2014; 19: 21-36.
20. Schwab JM, Serhan CN., Lipoxins and new lipid mediators in the resolution of inflammation. Curr Opin Pharmacol 2006; 6: 414-20.
21. Ricciotti E, FitzGerald GA., Prostaglandins and inflammation. Arterioscler Thromb Vasc Biol 2011; 31: 986-1000.
22. Petreaca ML, Do D, Dhall S, McLelland D, Serafino A, Lyubovitsky J, Schiller N, Martins-Green MM,. Deletion of a tumor necrosis superfamily gene in mice leads to impaired healing that mimics chronic wounds in humans. Wound Repair Regen 2012; 20: 353-66.
23. Dhall S, Do D, Garcia M, Wijesinghe DS, Brandon A, Kim J. A novel model of chronic wounds: importance of redox imbalance and biofilm-forming bacteria for establishment of chronicity. PLoS One 2014; 9: e109848.
24. Mietla JA, Wijesinghe DS, Hoeferlin LA, Shultz MD, Natarajan R, Fowler AA 3rd. Characterization of eicosanoid synthesis in a genetic ablation model of ceramide kinase. J Lipid Res 2013; 54: 1834-47.
25. Simanshu DK, Kamlekar RK, Wijesinghe DS, Zou X, Zhai X, Mishra SK. Non-vesicular trafficking by a ceramide-1-phosphate transfer protein regulates eicosanoids. Nature 2013; 500: 463-7.
26. Norton SK, Wijesinghe DS, Dellinger A, Sturgill J, Zhou Z, Barbour S. Epoxyeicosatrienoic acids are involved in the C70 fullerene derivative-induced control of allergic asthma. J Allergy Clin Immunol 2012; 130: 761-9.e2.
27. Wijesinghe DS, Brentnall M, Mietla JA, Hoeferlin LA, Diegelmann RF, Boise LH. Ceramide kinase is required for a normal eicosanoid response and the subsequent orderly migration of fibroblasts. J Lipid Res 2014; 55: 1298-309.
28. Hoeferlin LA, Huynh QK, Mietla JA, Sell SA, Tucker J, Chalfant CE. The lipid portion of activated platelet-rich plasma significantly contributes to its wound healing properties. Adv Wound Care 2015; 4: 100-9.
29. Paez Espinosa EV, Murad JP, Ting HJ, Khasawneh FT., Mouse transient receptor potential channel 6: role in hemostasis and thrombogenesis. Biochem Biophys Res Commun 2012; 417: 853-6.
30. Lin OA, Karim ZA, Vemana HP, Espinosa EVP, Khasawneh FT., The antidepressant 5-HT2A receptor antagonists pizotifen and cyproheptadine inhibit serotonin-enhanced platelet function. PLoS One 2014; 9: e87026.
31. Murad JP, Espinosa EVP, Ting HJ, Khasawneh FT., The C-terminal segment of the second extracellular loop of the thromboxane A2 receptor plays an important role in platelet aggregation. Biochem Pharmacol 2012; 83: 88-96.
32. Panigrahy D, Greene ER, Pozzi A, Wang DW, Zeldin DC., EET signaling in cancer. Cancer Metastasis Rev 2011; 30: 525-40.
33. Turner SR, Tainer JA, Lynn WS., Biogenesis of chemotactic molecules by the arachidonate lipoxygenase system of platelets. Nature 1975; 257: 680-1.
34. Node K, Huo Y, Ruan X, Yang B, Spiecker M, Ley K,. Anti-inflammatory Properties of Derived Eicosanoids. Science 1999; 285: 1276-9.
35. Medhora M, Daniels J, Mundey K, Fisslthaler B, Busse R, Jacobs ER,. Epoxygenase-driven angiogenesis in human lung microvascular endothelial cells. Am J Physiol Heart Circ Physiol 2003; 284: H215-24.
36. Spector AA, Norris AW., Action of epoxyeicosatrienoic acids on cellular function. AJP Cell Physiol 2006; 292: C996-1012.
37. Greene ER, Huang S, Serhan CN, Panigrahy D., Regulation of inflammation in cancer by eicosanoids. Prostaglandins Other Lipid Mediat 2011; 96: 27-36.
38. Samuelsson B, Dahlén SE, Lindgren JA, Rouzer CA, Serhan CN,. Leukiotrienes and lipoxins: structures, biosynthesis, and biological effects. Science 1987; 237: 1171-1176.
39. Hull MA, Booth JK, Tisbury A, Scott N, Bonifer C, Markham AF, Coletta PL,. Cyclooxygenase 2 is up-regulated and localized to macrophages in the intestine of Min mice. Br J Cancer 1999; 79: 1399-405.
40. Khasawneh FT, Huang JS, Mir F, Srinivasan S, Tiruppathi C, Le Breton GC,. Characterization of isoprostane signaling: evidence for a unique coordination profile of 8-iso-PGF(2alpha) with the thromboxane A(2) receptor, and activation of a separate cAMP-dependent inhibitory pathway in human platelets. Biochem Pharmacol 2008; 75: 2301-15.
41. Vijil C, Hermansson C, Jeppsson A, Bergström G, Hultén LM., Arachidonate 15-lipoxygenase enzyme products increase platelet aggregation and thrombin generation. PLoS One 2014; 9: e88546.
42. Vezza R, Roberti R, Nenci GG, Gresele P., Prostaglandin E2 potentiates platelet aggregation by priming protein kinase C. Blood 1993; 82: 2704-13.
43. Libby P, Warner S, Friedman G., Interleukin 1: a mitogen for human vascular smooth muscle cells that induces the release of growth-inhibitory prostanoids. J Clin Invest 1988; 81: 487-98.
44. Hamberg M, Svensson J, Samuelsson B., Thromboxanes: a new group of biologically active compounds derived from prostaglandin endoperoxides. Proc Natl Acad Sci USA 1975; 72: 2994-8.
45. Stevens MK, Yaksh TL., Time course of release in vivo of PGE2, PGF2a, 6-Keto PGF1a, and TxB2 into the brain extracellular space after 15 min of complete global ischemia in the presence and absence of cyclooxygenase inhibition. J Cereb Blood Flow Metab 1988; 8: 790-8.
46. Wijesinghe DS, Brentnall M, Boise LH, Chalfant CE., A lipidomics approach towards understanding eicosanoid signaling events and the role of ceramide kinase during the wound healing process. FASEB J 2011; 25: 551.15.
47. Lu Y, Tian H, Hong S., Novel 14,21-dihydroxy-docosahexaenoic acids: structures, formation pathways, and enhancement of wound healing. J Lipid Res 2010; 51: 923-32.
48. Patil K, Bellner L, Cullaro G, Gotlinger KH, Dunn MW, Schwartzman ML. Heme oxygenase-1 induction attenuates corneal inflammation and accelerates wound healing after epithelial injury. Invest Ophthalmol Vis Sci 2008; 49: 3379-86.
49. Norling LV, Spite M, Yang R, Flower RJ, Perretti M, Serhan CN. Cutting edge: humanized nano-proresolving medicines mimic inflammation-resolution and enhance wound healing. J Immunol 2011; 186: 5543-7.
50. Spector AA, Gordon JA, Moore SA., Hydroxyeicosatetraenoic acids (HETEs). Prog Lipid Res 1988; 27: 271-323.
51. Capdevila J, Marnett LJ, Chacos N, Prough RA, Estabrook RW., Cytochrome P-450-dependent oxygenation of arachidonic acid to hydroxyicosatetraenoic acids. Proc Natl Acad Sci USA 1982; 79: 767-70.
52. Goetzl EJ, Brash AR, Tauber AI, Oates JA, Howard WCHT., Modulation of human neutrophil function by monohydroxy-eicosatetraenoic acids. Immunology 1980; 30: 491-7.
53. Conrad DJ, Kuhn H, Mulkins M, Highland E, Sigal E., Specific inflammatory cytokines regulate the expression of human monocyte 15-lipoxygenase. Proc Natl Acad Sci USA 1992; 89: 217-21.
54. Rosolowsky M, Campbell WB., Role of PGI2 and epoxyeicosatrienoic acids in relaxation of bovine coronary arteries to arachidonic acid. Am J Physiol 1993; 264: H327-35.
55. Panigrahy D, Kalish BT, Huang S, Bielenberg DR, Le HD, Yang J. Epoxyeicosanoids promote organ and tissue regeneration. Proc Natl Acad Sci USA 2013; 110: 13528-33.
56. Pozzi A, Macias-Perez I, Abair T, Wei S, Su Y, Zent R. Characterization of 5,6- and 8,9-Epoxyeicosatrienoic Acids (5,6- and 8,9-EET) as Potent in Vivo Angiogenic Lipids. J Biol Chem 2005; 280: 27138-46.
57. Soter NA, Lewis RA, Corey EJ, Austen KF., Local effects of synthetic leukotrienes (LTC4,LTD4, and LTB4) in human skin. J Invest Dermatol 1983; 80: 115-9.
58. 4 induces subcellular β-catenin translocation and migration of colon cancer cells. Exp Cell Res 2014; 321: 255-66.
59. Stojadinovic O, Brem H, Vouthounis C, Lee B, Fallon J, Stallcup M. Molecular pathogenesis of chronic wounds: the role of beta-catenin and c-myc in the inhibition of epithelialization and wound healing. Am J Pathol 2005; 167: 59-69.
60. Paruchuri S, Tashimo H, Feng C, Maekawa A, Xing W, Jiang Y. Leukotriene E4-induced pulmonary inflammation is mediated by the P2Y12 receptor. J Exp Med 2009; 206: 2543-55.
61. Abd-El-Aleem SA, Morgan C, Mccollum CN, Ireland GW., Spatial distribution of mast cells in chronic venous leg ulcers. Eur J Histochem 2005; 49: 265-72.
62. Joris I, Majno G, Corey EJ, Lewis RA., The mechanism of vascular leakage induced by leukotriene E4. Endothelial contraction. Am J Pathol 1987; 126: 19-24.
63. Söder B., Neutrophil elastase activity, levels of prostaglandin E 2, and matrix metalloproteinase-8 in refractory periodontitis sites in smokers and non-smokers. Acta Odontol Scand 1999; 57: 77-82.
64. Grinnell F, Zhu M., Fibronectin degradation in chronic wounds depends on the relative levels of elastase, 1-proteinase inhibitor, and 2-macroglobulin. J Invest Dermatol 1996; 106: 335-41.
65. Chen SM, Ward SI, Olutoye OO, Diegelmann RF, Kelman Cohen I., Ability of chronic wound fluids to degrade peptide growth factors is associated with increased levels of elastase activity and diminished levels of proteinase inhibitors. Wound Repair Regen 1997; 5: 23-32
66. Herrick S, Ashcroft G, Ireland G, Horan M, McCollum C, Ferguson M. Up-regulation of elastase in acute wounds of healthy aged humans and chronic venous leg ulcers are associated with matrix degradation. Lab Invest 1997; 77: 281-8.
67. Harris SG, Padilla J, Koumas L, Ray D, Phipps RP., Prostaglandins as modulators of immunity. Trends Immunol 2002; 23: 144-50.
68. Norris PC, Dennis EA., A lipidomic perspective on inflammatory macrophage eicosanoid signaling. Adv Biol Regul 2014; 54: 99-110.
69. Needleman P, Wyche A, Raz A., Platelet and blood vessel arachidonate metabolism and interactions. J Clin Invest 1979; 63: 345-9.